Michael Paris

Michael Paris is an accomplished product development and operations executive with extensive experience in lifecycle management of innovative medical devices. He brings expertise in building and leading technology development and operations in early-stage ventures, as well as mature companies. Additionally, he has led and contributed to the successful regulatory authorizations (PMA and 510(k)) and commercial launch of numerous products. Prior to becoming CEO, Mr. Paris was Clinical Genomics’ Chief Operating Officer with oversight of all business subsidiaries. Prior to joining Clinical Genomics, he served as Chief Operating Officer and Senior Vice President, Operations and Technology Development, at Origin Inc., a biotechnology company. He had also held positions of increasing responsibility at Bioconnect Systems, a medical device company; Orthovita, Inc., which was acquired by Stryker Corporation in 2011, and Rex Medical, a medical device company specializing in the development, manufacturing, and marketing of innovative, minimally invasive medical devices. Mr. Paris received his BS degree in Mechanical Engineering Technology from Temple University, and an Executive MBA from Lebow College of Business, Drexel University.